Skip to main content

Advertisement

Log in

Management of Recurrent HCC After Liver Transplantation

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Liver transplantation is the best treatment option for hepatocellular carcinoma (HCC). Although centers use strict selection criteria, there is a risk of recurrence, reaching up to 20% which are mostly observed within two years following the procedure. The survival after the recurrence is poor and it has been reported to be between 7-16 months. This poor prognosis is due to the systemic course of the recurrence even its presentation is local initially.

Results

The clinical management and treatment algorithm of recurrence is challenging and there is no guideline regarding the situation. Staging of the disease and multi-disciplinary approach are important. The decision for choice of treatment is given depending on the localization and spread of the recurrence. Adjusting and switching the immunosuppressive therapy should be the first attempt. When the recurrence is limited or confined to resectable regions, surgery should be the choice of treatment. Multiple recurrence sites such as adrenal glands, lung, lymph nodes are not contraindication for curative surgery. Resection of the graft for intrahepatic recurrence is the most beneficial procedure for survival. If resection is not possible due to advanced hepatic disease, loco-regional therapies such as TACE, RF, microwave ablation should be considered. SBRT may be an alternative both for hepatic and extra-hepatic recurrence. In case of systemic disease, sorafenib should be the drug choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  CAS  Google Scholar 

  2. Rubin J, Ayoub N, Kaldas F, Saab S. Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review. Exp Clin Transplant. 2012;10:531–43.

    Article  Google Scholar 

  3. de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol. 2015;21:11185–98.

    Article  CAS  Google Scholar 

  4. Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: risk factors, screening and clinical presentation. World J Hepatol. 2019;11:261–72.

    Article  Google Scholar 

  5. Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg. 2017;266:118–25.

    Article  Google Scholar 

  6. Nagai S, Mangus RS, Kubal CA, Ekser B, Fridell JA, Klingler KR, et al. Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival. Clin Transpl. 2015;29:1156–63.

    Article  CAS  Google Scholar 

  7. Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol. 2015;22:2286–94.

    Article  CAS  Google Scholar 

  8. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534–40.

    Article  Google Scholar 

  9. Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, et al. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci. 2013;20:342–7.

    Article  Google Scholar 

  10. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;10:2031–5.

    Article  Google Scholar 

  11. Ringe B, Böker K, Schlitt HJ, Sproviero J, Hundrieser J, Tillmann HL, et al. Recurrence of hepatitis B virus cirrhosis and hepatocellular carcinoma: an indication for retransplantation? Clin Transpl. 1995;9:190–6.

    CAS  Google Scholar 

  12. Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm. World J Gastroenterol. 2018;24:5081–94.

    Article  CAS  Google Scholar 

  13. Duvoux C, Toso C. mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation? Transplant Rev (Orlando). 2015;29:168–74.

    Article  Google Scholar 

  14. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27:1039–49.

    Article  CAS  Google Scholar 

  15. Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2018;18:1435–46.

    Article  CAS  Google Scholar 

  16. Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–25.

    Article  CAS  Google Scholar 

  17. de’Angelis N, Landi F, Nencioni M, Palen A, Lahat E, Salloum C, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Prog Transplant. 2016;26:348–55.

    Article  Google Scholar 

  18. Gunay Y, Guler N, Akyildiz M, Yaprak O, Dayangac M, Yuzer Y, et al. Management of patients with recurrent hepatocellular carcinoma following living donor liver transplantation: a single center experience. Gulf J Oncol. 2014;1:12–8.

    CAS  Google Scholar 

  19. Hwang S, Kim YH, Kim DK, Ahn CS, Moon DB, Kim KH, et al. Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation. World J Surg. 2012;36:1592–602.

    Article  Google Scholar 

  20. Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int. 2020;7:S1499–3872(20)30116–8.

    Google Scholar 

  21. Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2016;200:122–30.

    Article  Google Scholar 

  22. Carr BI. Hepatic artery chemoembolization for hepatocellular carcinoma recurrence confined to the transplanted liver. Case Rep Oncol. 2012;5:506–10.

    Article  Google Scholar 

  23. Au KP, Chiang CL, Chan ACY, Cheung TT, Lo CM, Chok KSH. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation. World J Clin Cases. 2020;8:2758–68.

    Article  Google Scholar 

  24. Gringeri E, Boetto R, Bassi D, D'Amico FE, Polacco M, Romano M, et al. Laparoscopic microwave thermal ablation for late recurrence of local hepatocellular carcinoma after liver transplant: case report. Prog Transplant. 2014;24:142–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Baris Sarici.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sarici, B., Isik, B. & Yilmaz, S. Management of Recurrent HCC After Liver Transplantation. J Gastrointest Canc 51, 1197–1199 (2020). https://doi.org/10.1007/s12029-020-00498-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00498-6

Keywords

Navigation